A hydrogel-based tumor model for the evaluation of nanoparticle-based cancer therapeutics
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Three-dimensional (3D) tissue-engineered tumor models have the potential to bridge the gap between monolayer cultures and patient-derived xenografts for the testing of nanoparticle (NP)-based cancer therapeutics. In this study, a hydrogel-derived prostate cancer (PCa) model was developed for the in vitro evaluation of doxorubicin (Dox)-loaded polymer NPs (Dox-NPs). The hydrogels were synthesized using chemically modified hyaluronic acid (HA) carrying acrylate groups (HA-AC) or reactive thiols (HA-SH). The crosslinked hydrogel networks exhibited an estimated pore size of 70-100 nm, similar to the spacing of the extracellular matrices (ECM) surrounding tumor tissues. LNCaP PCa cells entrapped in the HA matrices formed distinct tumor-like multicellular aggregates with an average diameter of 50 μm after 7 days of culture. Compared to cells grown on two-dimensional (2D) tissue culture plates, cells from the engineered tumoroids expressed significantly higher levels of multidrug resistance (MDR) proteins, including multidrug resistance protein 1 (MRP1) and lung resistance-related protein (LRP), both at the mRNA and the protein levels. Separately, Dox-NPs with an average diameter of 54 ± 1 nm were prepared from amphiphilic block copolymers based on poly(ethylene glycol) (PEG) and poly(ε-caprolactone) (PCL) bearing pendant cyclic ketals. Dox-NPs were able to diffuse through the hydrogel matrices, penetrate into the tumoroid and be internalized by LNCaP PCa cells through caveolae-mediated endocytosis and macropinocytosis pathways. Compared to 2D cultures, LNCaP PCa cells cultured as multicellular aggregates in HA hydrogel were more resistant to Dox and Dox-NPs treatments. Moreover, the NP-based Dox formulation could bypass the drug efflux function of MRP1, thereby partially reversing the resistance to free Dox in 3D cultures. Overall, the engineered tumor model has the potential to provide predictable results on the efficacy of NP-based cancer therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536 · cited 1×
“Drug resistance remains an obstacle to effective chemotherapy of solid tumors [52], and has been attributed to the overexpression of the MDR proteins by tumor cells [12,14].”
BackgroundNile red: a selective fluorescent stain for intracellular lipid droplets.
Greenspan, P., Mayer, E. P., & Fowler, S. D. (1985) · The Journal of cell biology · doi:10.1083/jcb.100.3.965 · Cited by 2,543 · cited 1×
“This can be attributed to the fact that the fluorescence of the free dye was quenched in water [41].”
BackgroundNanomedicine: current status and future prospects
Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2005) · The FASEB Journal · doi:10.1096/fj.04-2747rev · Cited by 2,029 · cited 1×
“Encapsulating anti-cancer drugs in polymeric nanoparticles (NPs) are proposed, and in some cases have been shown, to improve the pharmacological properties of drugs [3].”
BackgroundCell and environment interactions in tumor microregions: the multicell spheroid model.
Sutherland, R. M. (1988) · Science · doi:10.1126/science.2451290 · Cited by 1,803 · cited 2×
“Such a unique microenvironment can exert both stimulatory and inhibitory effects on tumor progression [10].”
BackgroundFormulation of functionalized PLGA-PEG Nanoparticles for in vivo targeted drug delivery
Cheng, J., Teply, B. A., Sherifi, I., Sung, J., Luther, G., Gu, F. X., Levy-Nissenbaum, E., Radovic-Moreno, A. F., Langer, R., & Farokhzad, O. C. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2006.09.047 · Cited by 1,273
Loessner, D., Stok, K. S., Lutolf, M. P., Hutmacher, D. W., Clements, J. A., & Rizzi, S. C. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.07.064 · Cited by 602 · cited 1×
“poly(εcaprolactone) (PCL) [23], poly(lactic-co-glycolic acid) (PLGA) [24] and poly(ethylene glycol) (PEG) [25]) have been used as the scaffolding materials for the engineering of 3D tumor models.”
Method
Cited by
Three-dimensional in vitro tumor models for cancer research and drug evaluation
Xu, X., Farach-Carson, M. C., & Jia, X. (2014) · Biotechnology Advances · doi:10.1016/j.biotechadv.2014.07.009 · Cited by 461
Self-citationZhang, K., Feng, Q., Fang, Z., Gu, L., & Bian, L. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00071 · Cited by 394
Hydrogel microenvironments for cancer spheroid growth and drug screening
Li, Y., & Kumacheva, E. (2018) · Science Advances · doi:10.1126/sciadv.aas8998 · Cited by 351
Three‑dimensional cell culture: A powerful tool in tumor research and drug discovery (Review)
Lv, D., Hu, Z., Lu, L., Lu, H., & Xu, X. (2017) · Oncology Letters · doi:10.3892/ol.2017.7134 · Cited by 337
Self-citationHuang, B.-W., & Gao, J.-Q. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.12.005 · Cited by 174
Metadata
- Authors
- Xu, X., Sabanayagam, C. R., Harrington, D. A., Farach-Carson, M. C., & Jia, X.
- Venue
- Biomaterials
- Publisher
- Elsevier BV
- Published
- 2014-03
- Volume
- 35
- Issue
- 10
- Pages
- 3319-3330
- ISSN
- 0142-9612 (ISSN-L)
- OpenAlex
- W1991517939
- Cited by
- 117
- References
- 6
- FWCI
- 4.90
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.